The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis
{{output}}
Background: The efficacy and immune-mediated safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer (TNBC) remain controversial. Given TNBC's aggressive biology and poor prognosis, definitive evidence is urgently neede... ...
